Investment
Features
FeesSafety
Academy
More
Pluang+

BlackRock buys over $1 billion in Bitcoin amid market uncertainty, boosting its holdings to $61 billion.

Market News
15 Sep 2026
UToday
View Source
Bullish
BlackRock buys over $1 billion in Bitcoin amid market uncertainty, boosting its holdings to $61 billion.

BlackRock has purchased more than $1 billion worth of Bitcoin in the past 20 days, increasing its total Bitcoin holdings to approximately 785,900 BTC valued at around $61 billion. This move highlights strong institutional demand for Bitcoin through BlackRock's iShares Bitcoin Trust (IBIT), which has seen steady capital inflows. Meanwhile, competitors like Grayscale have experienced net outflows, indicating a shift in investor confidence towards BlackRock's Bitcoin products despite volatile market conditions. BlackRock's continued accumulation positions it as a dominant player in institutional Bitcoin investment.

BlackRock's recent $1 billion Bitcoin purchase provides context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Sep 15, 2026 17:31 WIB: Among 50 major cryptocurrencies, 13 rose and 36 fell today. Notable movers include XLM (Stellar) at Rp3.446 with a 1-day change of +4.14% and a typical hold time of 83 days, GRT (The Graph) at Rp316 with -3.79% change and 98 days hold time, and KSM (Kusama) at Rp68.112 with -3.72% change and a 79-day hold time. Pluang order activity shows mixed buy and sell interest across these assets.

More News

Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma A/S regained full control of its TransCon technology for metabolic diseases from Novo Nordisk, allowing it to independently develop and sell treatments, including for obesity. The company also authorized a $400 million share repurchas...

Market News
Bullish
3 hours ago
Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.

Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.

Deutsche Bank upgraded AstraZeneca's stock rating from Sell to Hold following mixed results from its drug trials. The lung disease drug tozorakimab showed strong Phase III results and received FDA priority review, signaling potential future growth. H...

Analyst Insights
Neutral
3 hours ago
Tesla rebounds with 52% US EV market share despite past sales collapse and political fallout.

Tesla rebounds with 52% US EV market share despite past sales collapse and political fallout.

Tesla's US market share has recovered to 52% after a sharp decline in 2025 linked to CEO Elon Musk's political ties, which hurt brand loyalty and wiped out over $500 billion in market value. While overall US EV sales dropped 30% through August 2026, ...

Market News
Bullish
4 hours ago
Oracle stock set for 121% rebound as cloud growth and AI boost optimism.

Oracle stock set for 121% rebound as cloud growth and AI boost optimism.

Oracle's stock has fallen over 52% in the past year but is expected to recover strongly, with Mizuho Securities predicting a 121% rise to $320 in the next 12 months. This optimism is driven by accelerating cloud infrastructure growth and disciplined ...

Analyst Insights
Bullish
4 hours ago
Musk and Cramer agree AI panic is driven by profit motives but differ on investor impact and safety solutions.

Musk and Cramer agree AI panic is driven by profit motives but differ on investor impact and safety solutions.

Elon Musk and Jim Cramer both suspect that AI doom warnings from leading labs are motivated by commercial interests. Musk proposes a peer-review safety system where AI companies test each other's models to prevent harmful behavior, emphasizing the ne...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App